The Challenges and Opportunities Associated with Reimbursement for Obesity Pharmacotherapy in the USA

PharmacoEconomics

Volumn 33, Issue 7, 2015, Pages 643-653

  Baum, Charles ^a   Andino, Katherine ^a   Wittbrodt, Eric ^a   Stewart, Shelley ^b   Szymanski, Keith ^a   Turpin, Robin ^a  

^a TAKEDA PHARMACEUTICALS   (United States)

^b Takeda Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EDITORIAL; EMPLOYER; HEALTH CARE; HEALTH CARE POLICY; HUMAN; MARKET; MEDICAL SOCIETY; OBESITY; PERCEPTION; PHARMACEUTICAL CARE; PHYSICIAN; PRIORITY JOURNAL; REIMBURSEMENT; UNITED STATES; ECONOMICS; LIFESTYLE;

ANTIOBESITY AGENT;

ANTI-OBESITY AGENTS; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; LIFE STYLE; OBESITY; UNITED STATES;

EID: 84933677128     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-015-0264-0     Document Type: Editorial

References (123)

1. Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014;129(25 Suppl 2):S102–38.
2. Organization for Economic Co-operation and Development. Obesity and the economics of prevention. Geneva: Organization for Economic Co-operation and Development Publishing; 2010.
3. Organization for the Economic Co-operation and Development. Obesity update. June 2014. June 2014. http://www.oecd.org/els/health-systems/Obesity-Update-2014.pdf. Accessed 29 July 2014.
4. Wang Y, Beydoun MA. The obesity epidemic in the United States—gender, age, socioeconomic, racial/ethnic, and geographic characteristics: a systematic review and meta-regression analysis. Epidemiol Rev. 2007;29:6–28.
5. Mitchell NS, Catenacci VA, Wyatt HR, Hill JO. Obesity: overview of an epidemic. Psychiatr Clin North Am. 2011;34(4):717–32.
6. Komlos J, Brabec M. The trend of mean BMI values of US adults, birth cohorts 1882–1986 indicates that the obesity epidemic began earlier than hitherto thought. Am J Hum Biol. 2010;22(5):631–8.
7. Office of the Surgeon General (US); Office of Disease Prevention and Health Promotion (US); Centers for Disease Control and Prevention (US); National Institutes of Health (US). The Surgeon General’s call to action to prevent and decrease overweight and obesity. Rockville: office of the Surgeon General (US); 2001. http://www.ncbi.nlm.nih.gov/pubmed/20669513. Accessed 28 May 2014.
8. Swinburn BA, Caterson I, Seidell JC, James WPT. Diet, nutrition and the prevention of excess weight gain and obesity. Public Health Nutr. 2004;7(1A):123–46.
9. Hill JO. Can a small-changes approach help address the obesity epidemic? A report of the Joint Task Force of the American Society for Nutrition, Institute of Food Technologists, and International Food Information Council. Am J Clin Nutr. 2009;89(2):477–84.
10. Wilde PE. Federal communication about obesity in the Dietary Guidelines and checkoff programs. Obesity (Silver Spring). 2006;14(6):967–73.
11. Office for State, tribal, local and territorial support. Nutrition, physical activity, and obesity. In: Centers for Disease Control and Prevention. Prevention Status Reports (PSR). 2013. http://www.cdc.gov/stltpublichealth/psr/npao/index.html. Accessed 29 May 2014.
12. National Center for Chronic Disease Prevention and Health Promotion, Division of Nutrition Physical Activity and Obesity, Centers for Disease Control and Prevention. State indicator report on fruits and vegetables, 2013. National action guide. http://www.cdc.gov/nutrition/downloads/national-action-guide2013.pdf. Accessed 29 May 2014.
13. Dietz WH, Benken DE, Hunter AS. Public health law and the prevention and control of obesity. Milbank Q. 2009;87(1):215–27.
14. Mello MM, Studdert DM, Brennan TA. Obesity—the new frontier of public health law. N Engl J Med. 2006;354(24):2601–10.
15. Obesity Education Initiative, National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. National Institutes of Health. Sep 1998. http://www.nhlbi.nih.gov/files/docs/guidelines/ob_gdlns.pdf. Accessed 5 May 2014.
16. Rippe JM. The case for medical management of obesity: a call for increased physician involvement. Obes Res. 1998;6(Suppl 1):23S–33S.
17. Lemmens VEPP, Oenema A, Klepp KI, Henriksen HB, Brug J. A systematic review of the evidence regarding efficacy of obesity prevention interventions among adults. Obes Rev. 2008;9(5):446–55.
18. Lombard CB, Deeks AA, Teede HJ. A systematic review of interventions aimed at the prevention of weight gain in adults. Public Health Nutr. 2009;12(11):2236–46.
19. Brown T, Summerbell C. Systematic review of school-based interventions that focus on changing dietary intake and physical activity levels to prevent childhood obesity: an update to the obesity guidance produced by the National Institute for Health and Clinical Excellence. Obes Rev. 2009;10(1):110–41.
20. Wolf AM, Woodworth KA. Obesity prevention: recommended strategies and challenges. Am J Med. 2009;122(4 Suppl 1):S19–23.
21. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403.
22. Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, Brenneman AT, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374(9702):1677–86.
23. Moore AF, Jablonski KA, Mason CC, McAteer JB, Arakaki RF, Goldstein BJ, et al. The association of ENPP1 K121Q with diabetes incidence is abolished by lifestyle modification in the diabetes prevention program. J Clin Endocrinol Metab. 2009;94(2):449–55.
24. Wing RR, Lang W, Wadden TA, Safford M, Knowler WC, Bertoni AG, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011;34(7):1481–6.
25. Korytkowski MT. Lessons from the look action for health in diabetes study. Indian J Endocrinol Metab. 2013;17(Suppl 3):S650–3.
26. Loveman E, Frampton GK, Shepherd J, Picot J, Cooper K, Bryant J, et al. The clinical effectiveness and cost-effectiveness of long-term weight management schemes for adults: a systematic review. Health Technol Assess. 2011;15(2):1–182.
27. Allison DB, Downey M, Atkinson RL, Billington CJ, Bray GA, Eckel RH, et al. Obesity as a disease: a white paper on evidence and arguments commissioned by the Council of the Obesity Society. Obesity (Silver Spring). 2008;16(6):1161–77.
28. Pi-Sunyer X. The medical risks of obesity. Postgrad Med. 2009;121(6):21–33.
29. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al. AACE comprehensive diabetes management algorithm 2013. Endocr Pract. 2013;19(2):327–36.
30. Alexander SC, Cox ME, Boling Turer CL, Lyna P, Østbye T, Tulsky JA, et al. Do the five A’s work when physicians counsel about weight loss? Fam Med. 2011;43(3):179–84.
31. H.R. 3590—111th Congress: Patient Protection and Affordable Care Act. Public Law No. 111-148. 124 Stat. 119-1025. 23 March 2010. http://www.gpo.gov/fdsys/pkg/BILLS-111hr3590enr/pdf/BILLS-111hr3590enr.pdf. Accessed 6 May 2014.
32. Skinner AC, Skelton JA. Prevalence and trends in obesity and severe obesity among children in the United States, 1999–2012. JAMA Pediatr. 2014;168(6):561–6.
33. Zhao Y, Encinosa W. Bariatric surgery utilization and outcomes in 1998 and 2004. HCUP Statistical Brief #23. Agency for Healthcare Research and Quality. January 2007. http://www.hcup-us.ahrq.gov/reports/statbriefs/sb23.pdf. Accessed 11 Dec 2014.
34. U.S. Food and Drug Administration. FDA expands use of banding system for weight loss [press Announcement]. 2011 Feb 16. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm245617.htm. Accessed 11 Dec 2014.
35. O’Brien PE, MacDonald L, Anderson M, Brennan L, Brown WA. Long-term outcomes after bariatric surgery: fifteen-year follow-up of adjustable gastric banding and a systematic review of the bariatric surgical literature. Ann Surg. 2013;257(1):87–94.
36. Picot J, Jones J, Colquitt JL, Gospodarevskaya E, Loveman E, Baxter L, et al. The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation. Health Technol Assess (Rockv). 2009;13(41):1–190, 215–357, 3–4.
37. Maggard MA, Shugarman LR, Suttorp M, Maglione M, Sugerman HJ, Sugarman HJ, et al. Meta-analysis: surgical treatment of obesity. Ann Intern Med. 2005;142(7):547–59.
38. Karmali S, Brar B, Shi X, Sharma AM, de Gara C, Birch DW. Weight recidivism post-bariatric surgery: a systematic review. Obes Surg. 2013;23(11):1922–33.
39. Hsu LK, Benotti PN, Dwyer J, Roberts SB, Saltzman E, Shikora S, et al. Nonsurgical factors that influence the outcome of bariatric surgery: a review. Psychosom Med. 1998;60(3):338–46.
40. Brethauer SA, Kothari S, Sudan R, Williams B, English WJ, Brengman M, et al. Systematic review on reoperative bariatric surgery: American Society for Metabolic and Bariatric Surgery Revision Task Force. Surg Obes Relat Dis. 2014;10(5):952–72. doi:10.1016/j.soard.2014.02.014.
41. Steinberg DM, Tate DF, Bennett GG, Ennett S, Samuel-Hodge C, Ward DS. The efficacy of a daily self-weighing weight loss intervention using smart scales and e-mail. Obesity (Silver Spring). 2013;21(9):1789–97.
42. Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. JAMA. 2014;311(1):74–86.
43. Finkelstein EAE, Trogdon JGJ, Cohen JJW, Dietz W. Annual medical spending attributable to obesity: payer-and service-specific estimates. Health Aff. 2009;28(5):w822–31.
44. Rothberg AE, McEwen LN, Fraser T, Burant CF, Herman WH. The impact of a managed care obesity intervention on clinical outcomes and costs: a prospective observational study. Obesity (Silver Spring). 2013;21(11):2157–62. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3947418&tool=pmcentrez&rendertype=abstract. Accessed 5 May 2014.
45. Colman E. Anorectics on trial: a half century of federal regulation of prescription appetite suppressants. Ann Intern Med. 2005;143(5):380–5.
46. Stamler J. Epidemic obesity in the United States. Arch Intern Med. 1993;153(9):1040–4.
47. Lexchin J. Lifestyle drugs: issues for debate. CMAJ. 2001;164(10):1449–51.
48. Yale C. Reporting our results. Obes Surg. 1991;1(3):241–2.
49. Cohen K. Fen phen nation. In: Frontline. WGBH Educational Foundation. 2003 Nov 13. http://www.pbs.org/wgbh/pages/frontline/shows/prescription/hazard/fenphen.html. Accessed 30 May 2014.
50. Meyer BR. Powerful medicines: the benefits, risks, and costs of prescription drugs. Ann Intern Med. 2005;142(1):80.
51. Center for Drug Evaluation and Research, U.S. Food and Drug Administration. FDA announces withdrawal fenfluramine and dexfenfluramine (fen-phen). In: Postmarket Drug Safety Information for Patients and Providers. Center for Drug Evaluation and Research, U.S. Food and Drug Administration. 1997. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm179871.htm. Accessed 30 May 2014.
52. McBay DL, Dourish CT. Obesity—the 21st century disease. Drug Discov World. 2002;18–24.
53. Thomson Reuters. Spotlight on…obesity. A pharma matters report. Oct–Dec 2010. http://ip-science.thomsonreuters.com.au/m/pdf/SpotlightOn_cwp_Q4_10.pdf. Accessed 6 May 2014.
54. Wong D, Sullivan K, Heap G. The pharmaceutical market for obesity therapies. Nat Rev Drug Discov. 2012;11(9):669–70.
55. U.S. Food and Drug Administration. FDA approves Belviq to treat some overweight or obese adults. In: Press Announcements. U.S. Food and Drug Administration. 2012. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm309993.htm. Accessed 29 July 2014.
56. U.S. Food and Drug Administration. FDA approves weight-management drug Qsymia. In: Press Announcements. U.S. Food and Drug Administration. 2012. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm312468.htm. Accessed 3 June 2014.
57. U.S. Food and Drug Administration. FDA approves weight-management drug Contrave. In: Press Announcements. U.S. Food and Drug Administration. 2014. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm413896.htm. Accessed 11 Dec 2014.
58. Goozner M. FDA increases focus on postmarketing studies. J Natl Cancer Inst. 2010;102(17):1302–4.
59. DiMasi JA, Feldman L, Seckler A, Wilson A. Trends in risks associated with new drug development: success rates for investigational drugs. Clin Pharmacol Ther. 2010;87(3):272–7.
60. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev drug Discov. 2004;3(8):711–5.
61. Adams CP, Brantner VV. Spending on new drug development. Health Econ. 2010;19(2):130–41.
62. Vernon JA, Golec JH, Dimasi JA. Drug development costs when financial risk is measured using the Fama-French three-factor model. Health Econ. 2010;19(8):1002–5.
63. Morgan S, Grootendorst P, Lexchin J, Cunningham C, Greyson D. The cost of drug development: a systematic review. Health Policy. 2011;100(1):4–17.
64. Heal DJ, Gosden J, Smith SL. Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders. Br J Clin Pharmacol. 2009;68(6):861–74.
65. Hayes WS. Bridging the evidence gap to treat obesity. In: Hayes Blog. Winifred S. Hayes, Inc. 2013. http://www.hayesinc.com/hayes/blog/blog-bridging-the-evidence-gap-to-treat-obesity/. Accessed 3 June 2014.
66. Snow V, Barry P, Fitterman N, Qaseem A, Weiss K. Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2005;142(7):525.
67. ECRI Institute. Priority area 10: obesity. AHRQ Healthcare Horizon Scanning System—potential high-impact interventions report. Rockville: Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services; 2013 Dec. http://effectivehealthcare.ahrq.gov/ehc/assets/File/Obesity-Horizon-Scan-High-Impact-1312.pdf. Accessed 15 May 2014.
68. Greenapple R, Ngai J. Obesity: effective treatment requires change in payers’ perspective. Am Heal Drug Benefits. 2010;3(2):88–94.
69. Verger P, Rolland S, Paraponaris A, Bouvenot J, Ventelou B. Drug reimbursement and GPs’ prescribing decisions: a randomized case-vignette study about the pharmacotherapy of obesity associated with type 2 diabetes: how GPs react to drug reimbursement. Fundam Clin Pharmacol. 2010;24(4):509–16.
70. U.S. Food and Drug Administration. Meridia (sibutramine): market withdrawal due to risk of serious cardiovascular events. In: Safety alerts for human medical products. U.S. Food and Drug Administration. 2010. http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm228830.htm. Accessed 29 July 2014.
71. Yang YT, Nichols LM. Obesity and health system reform: private vs. public responsibility. J Law Med Ethics. 2011;39(3):380–6.
72. Epstein AM, Jha AK, Orav EJ, Liebman DL, Audet A-MJ, Zezza MA, et al. Analysis of early accountable care organizations defines patient, structural, cost, and quality-of-care characteristics. Health Aff (Millwood). 2014;33(1):95–102.
73. Health Information Technology for Economic and Clinical Health Act. 123 Stat. 226, 467. 17 February 2009. http://www.gpo.gov/fdsys/pkg/BILLS-111hr1enr/pdf/BILLS-111hr1enr.pdf. Accessed 6 May 2014.
74. Centers for Medicare and Medicaid Services. EHR incentive programs. In: CMS—regulations and guidance. Centers for Medicare and Medicaid Services. 2014. http://www.cms.gov/Regulations-and-Guidance/Legislation/EHRIncentivePrograms/index.html?redirect=/ehrincentiveprograms/. Accessed 6 May 2014.
75. American Medical Association Council on Science and Public Health, American Medical Association. Recognition of Obesity as a Disease. Resolution: 421(A-13). American Medical Association. May 2013. http://media.npr.org/documents/2013/jun/ama-resolution-obesity.pdf. Accessed 6 May 2014.
76. Zuzek C. Obesity is a disease. Tex Med. 2014;110(1):45–8.
77. The American Association of Clinical Endocrinologists. Press Statement [AACE letter to members regarding updated guidelines on lipids and obesity by AHA/ACC/TOS]. 2013. https://www.aace.com/sites/all/files/Member_Alert_Re_Guidelines_112113.pdf. Accessed 6 May 2014.
78. Rippe JM, Crossley S, Ringer R. Obesity as a chronic disease: modern medical and lifestyle management. J Am Diet Assoc. 1998;98(10 Suppl 2):S9–15.
79. Obesity as a disease: the Obesity Society Council resolution. Obesity (Silver Spring). 2008;16(6):1151.
80. Kopelman PG. Obesity as a medical problem. Nature. 2000;404(6778):635–43.
81. Conway B, Rene A. Obesity as a disease: no lightweight matter. Obes Rev. 2004;5(3):145–51.
82. Engelhard CL, Garson A, Dorn S. Reducing obesity: policy strategies from the tobacco wars. Methodist Debakey Cardiovasc J. 2009;5(4):46–50.
83. Rao G. Office-based strategies for the management of obesity. Am Fam Physician. 2010;81(12):1449–56 (quiz 1429).
84. Bray GA. Are non-prescription medications needed for weight control? Obesity (Silver Spring). 2008;16(3):509–14.
85. Patterson L, Patterson C, Kee F, Hughes C, Donnelly M, O’Reilly D. Prescribing for weight loss in primary care: evidence from a population based study. J Epidemiol Community Health. 2013;67(6):530–2.
86. Blackburn G. Effect of degree of weight loss on health benefits. Obes Res. 1995;3(S2):211s–6s.
87. Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord. 1992;16(6):397–415.
88. Van Gaal LF. What is the relationship between risk factor reduction and degree of weight loss? Eur Hear J Suppl. 2005;7(Suppl L):L21–6.
89. Varady KA, Tussing L, Bhutani S, Braunschweig CL. Degree of weight loss required to improve adipokine concentrations and decrease fat cell size in severely obese women. Metabolism. 2009;58(8):1096–101.
90. Foster GD, Wadden TA, Phelan S, Sarwer DB, Sanderson RS. Obese patients’ perceptions of treatment outcomes and the factors that influence them. Arch Intern Med. 2001;161(17):2133–9.
91. Hemo B, Endevelt R, Porath A, Stampfer MJ, Shai I. Adherence to weight loss medications; post-marketing study from HMO pharmacy data of one million individuals. Diabetes Res Clin Pract. 2011;94(2):269–75.
92. Phelan S, Nallari M, Darroch FE, Wing RR. What do physicians recommend to their overweight and obese patients? J Am Board Fam Med. 2009;22(2):115–22.
93. Stafford RS, Farhat JH, Misra B, Schoenfeld DA. National patterns of physician activities related to obesity management. Arch Fam Med. 2000;9(7):631–8.
94. Foster GD, Wadden TA, Makris AP, Davidson D, Sanderson RS, Allison DB, et al. Primary care physicians’ attitudes about obesity and its treatment. Obes Res. 2003;11(10):1168–77.
95. Epling JW, Morley CP, Ploutz-Snyder R. Family physician attitudes in managing obesity: a cross-sectional survey study. BMC Res Notes. 2011;4:473.
96. Yanovski SZ, Yanovski JA. Obesity. N Engl J Med. 2002;346(8):591–602.
97. Bleich SN, Pickett-Blakely O, Cooper LA. Physician practice patterns of obesity diagnosis and weight-related counseling. Patient Educ Couns. 2011;82(1):123–9.
98. Lazorick S, Peaker B, Perrin EM, Schmid D, Pennington T, Yow A, et al. Prevention and treatment of childhood obesity: care received by a state Medicaid population. Clin Pediatr (Phila). 2011;50(9):816–26.
99. Tham M, Young D. The role of the General Practitioner in weight management in primary care—a cross sectional study in General Practice. BMC Fam Pract. 2008;9:66.
100. Forman-Hoffman V, Little A, Wahls T. Barriers to obesity management: a pilot study of primary care clinicians. BMC Fam Pract. 2006;7:35.
101. Bennett GG, Steinberg DM, Stoute C, Lanpher M, Lane I, Askew S, et al. Electronic health (eHealth) interventions for weight management among racial/ethnic minority adults: a systematic review. Obes Rev. 2014;15(Suppl 4):146–58.
102. Yeager SF, Heim R, Seiler J, Lofton H. Self-monitoring—the way to successful weight management. Your Weight Matters Magazine. 2014;5. http://www.obesityaction.org/educational-resources/resource-articles-2/weight-loss-surgery/self-monitoring-the-way-to-successful-weight-management. Accessed 11 Dec 2014.
103. Holtorf A, Rinde H, Rupprecht F, Alder H, Brixner D. The economic impact of bariatric surgery, advanced bariatric and metabolic surgery. In: Huang C-K, editor. Rijeka: InTech; 2012.
104. Finkelstein EA, Kruger E. Meta- and cost-effectiveness analysis of commercial weight loss strategies. Obesity (Silver Spring). 2014;22(9):1942–51.
105. Risser JA, Vash PD, Nieto L. Does prior authorization of sibutramine improve medication compliance or weight loss? Obes Res. 2005;13(1):86–92.
106. U.S. Office of Personnel Management Healthcare and Insurance. Supplemental guidance: management of obesity in adults. In: FEHB Program Carrier Letter. 2014. http://www.opm.gov/healthcare-insurance/healthcare/carriers/2014/2014-04.pdf. Accessed 29 July 2014.
107. The Advisory Board Company. Feds offer guidance on how to cover obesity treatment—OPM sets standards of federal employee health plans. In: Daily Briefing. The Advisory Board Company. 2014. http://www.advisory.com/daily-briefing/2014/04/03/feds-offer-guidance-on-how-to-cover-obesity-treatment. Accessed 5 May 2014.
108. Medicare Prescription Drug, Improvement, and Modernization Act of 2003. Public Law No. 108-173. 2003. http://www.gpo.gov/fdsys/pkg/PLAW-108publ173/html/PLAW-108publ173.htm. Accessed 29 July 2014.
109. The Omnibus Budget Reconciliation Act of 1990. Sec 1927(d)(2). 1990. http://www.ssa.gov/OP_Home/ssact/title19/1927.htm. Accessed 5 May 2014.
110. Department of Health and Human Services (DHHS), Centers for Medicare and Medicaid Services (CMS). Chapter 6—Part D Drugs and Formulary Requirements. CMS Manual System Pub. 100-18: Medicare Prescription Drug Benefit Manual. July 2008. http://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/downloads/R2PDB.pdf. Accessed 5 May 2014.
111. S. 1184–113th Congress: Treat and Reduce Obesity Act of 2013. 2013. http://www.govtrack.us/congress/bills/113/s1184. Accessed 5 May 2014.
112. H.R. 2415: Treat and Reduce Obesity Act of 2013. 2013. https://www.govtrack.us/congress/bills/113/hr2415. Accessed 5 May 2014.
113. Carvajal R, Wadden TA, Tsai AG, Peck K, Moran CH. Managing obesity in primary care practice: a narrative review. Ann NY Acad Sci. 2013;1281:191–206.
114. Lee JS, Sheer JLO, Lopez N, Rosenbaum S. Coverage of obesity treatment: a state-by-state analysis of Medicaid and state insurance laws. Public Health Rep. 2010;125(4):596–604.
115. New York State Department of Health. Specific strategies. In: Strategic plan for overweight and obesity prevention. New York State Department of Health. 2014. http://www.aging.ny.gov/news/2013/Strategic_plan%20NYSDOH%20Obesity%202005.pdf. Accessed 29 May 2014.
116. U.S. Centers for Disease Control and Prevention. Health plan implementation of U.S. Preventive Services Task Force A and B recommendations–Colorado, 2010. MMWR Morb Mortal Wkly Rep. 2011;60(39):1348–50.
117. RTI International, Telligen. Accountable Care Organization 2013 program analysis. Quality performance standards narrative measure specifications. Centers for Medicare and Medicaid Services. December 2012. http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/sharedsavingsprogram/Downloads/ACO-NarrativeMeasures-Specs.pdf. Accessed 5 May 2014.
118. Centers for Medicare and Medicaid Services. Part C and D performance data. In: Prescription Drug Coverage—General Information. Centers for Medicare and Medicaid Services. 2014. http://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovGenIn/PerformanceData.html. Accessed 5 May 2014.
119. National Committee for Quality Assurance (NCQA). Summary table of measures, product lines and changes. In: HEDIS 2014. Healthcare Effectiveness Data and Information Set (HEDIS). 2014. http://www.ncqa.org/Portals/0/HEDISQM/HEDIS2014/List_of_HEDIS_2014_Measures.pdf. Accessed 5 May 2014.
120. DeNavas-Walt C, Proctor BD, Smith JC. Income, poverty, and health insurance coverage in the United States: 2011. U.S. Census Bureau, Current Population Reports, P60-243. U.S. Government Printing Office. September 2012. http://www.census.gov/prod/2012pubs/p60-243.pdf. Accessed 10 July 2014.
121. Horwitz JR, Kelly BD, DiNardo JE. Wellness incentives in the workplace: cost savings through cost shifting to unhealthy workers. Health Aff (Millwood). 2013;32(3):468–76.
122. Neve M, Morgan PJ, Jones PR, Collins CE. Effectiveness of web-based interventions in achieving weight loss and weight loss maintenance in overweight and obese adults: a systematic review with meta-analysis. Obes Rev. 2010;11(4):306–21.
123. Leahey TM, Subak LL, Fava J, Schembri M, Thomas G, Xu X, et al. Benefits of adding small financial incentives or optional group meetings to a web-based statewide obesity initiative. Obesity (Silver Spring). 2015;23(1):70–6. doi:10.1002/oby.20937.